SCHEMBL3613910

SCHEMBL3613910

O=c1c(-c2cccnc2)c[nH]n1-c1ccc(CO)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
VHL P40337 7/20 1.00
P4HTM Q9NXG6 12/20 0.76
EGLN1 Q9GZT9 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3596846 0.99 VHL (0.98) VHLP4HTMEGLN1
SCHEMBL8194546 0.89 VHL (0.81) VHLP4HTMEGLN1
Hydrochloric Acid SCHEMBL3610220 0.88 VHL (0.79) VHLP4HTMEGLN1
SCHEMBL8191975 0.86 P4HTM (1.00) VHLP4HTMEGLN1
SCHEMBL8182373 0.86 VHL (0.76) VHLP4HTMEGLN1
SCHEMBL8182183 0.86 VHL (0.76) VHLP4HTMEGLN1
Hydrochloric Acid SCHEMBL3613972 0.85 VHL (0.74) VHLP4HTMEGLN1
Hydrochloric Acid SCHEMBL3620423 0.85 P4HTM (0.98) VHLP4HTMEGLN1
Hydrochloric Acid SCHEMBL3621469 0.85 VHL (0.74) VHLP4HTMEGLN1
SCHEMBL8257398 0.85 VHL (1.00) VHLP4HTMEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097404-B1 SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF BAYER IP GMBH (DE) 2016-07-27 EP disclosed
US-9085572-B2 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-07-21 US disclosed
US-9085572-B2 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-07-21 US disclosed
US-8609698-B2 Substituted dipyridyl-dihydropyrazolones and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-12-17 US disclosed
US-20120322772-A1 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-20 US disclosed
US-20120322772-A1 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-20 US disclosed
US-8252817-B2 Dipyridyl-dihydropyrazolones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-28 US disclosed
US-20100093803-A1 SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) 2010-04-15 US disclosed
US-20100035906-A1 Dipyridyl-dihydropyrazolones and their use BAYER HEALTHCARE AG (DE) 2010-02-11 US disclosed
WO-2006114213-A1 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES BAYER HEALTHCARE AG (DE) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093803-A1 SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF DCK, THPO, QDPR VHL 25/4885P4HTM 412/4885EGLN1 882/4885
US-20120322772-A1 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES PPIP5K2, THPO, DPYD VHL 35/4885P4HTM 657/4885EGLN1 1855/4885
US-20100035906-A1 Dipyridyl-dihydropyrazolones and their use DPP7, DPP4, QDPR VHL 38/4885P4HTM 633/4885EGLN1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.